Skip to main content
. 2019 Sep 16;25:1076029619872556. doi: 10.1177/1076029619872556

Table 1.

Multiple reaction monitoring transitions and optimized mass spectrometry parameters for the analyzed compounds.

Compound (I, II—First and Second MRM Transitions) MRM Transition (m/z) Dwell Time (ms) Declustering Potential (V) Entrance Potential (V) Collision Energy (V) Collision Cell Exit Potential (V) Limit of Quantitation (ng/mL)
Apixaban I 460.1 → 199.1 20 196 10 53 8 0.22
Apixaban II 460.1 → 185.1 20 196 10 55 12 1.06
DAB-D3 I 475.2 → 292.1 100 146 10 39 18 -
DAB-D3 II 475.2 → 175.1 100 146 10 55 10 -
Dabigatran I 472.1 → 289.0 100 126 10 39 6 0.57
Dabigatran II 472.1 → 324.1 100 126 10 29 8 1.18
Rivaroxaban I 436.0 → 144.8 160 156 10 33 18 0.79
Rivaroxaban II 436.0 → 231.0 160 156 10 29 20 3.38

Abbreviations: DAB-D3, deuterated analogue ofdabigatran; MRM, multiple reaction monitoring.